首页> 外国专利> New monoclonal anti-idiotypic antibody is human anti-factor-VIII inhibitor useful to treat haemophilia-A

New monoclonal anti-idiotypic antibody is human anti-factor-VIII inhibitor useful to treat haemophilia-A

机译:新型单克隆抗独特型抗体是可用于治疗A型血友病的人类抗VIII因子抑制剂

摘要

A monoclonal anti-idiotypic antibody (I) for targeting an antibody inhibiting the human factor VIII, is new, where (I) targets the C2 region of the human factor-VIII in which the variable region of each of the light chains is encoded by a sequence of nucleic acids identical to the murine sequence of nucleic acids (SEQ ID No: 1), the variable region of each of the heavy chains is encoded by a sequence of nucleic acids identical to the murine sequence of nucleic acids (SEQ ID No: 2) and the constant regions of the light and heavy chains are constant regions of a murine species. Monoclonal anti-idiotypical antibody (I) to target an antibody inhibiting the human factor VIII, is new, where (I) target the C2 region of the human factor VIII in which the variable region of each of the light chains is encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids having a fully defined 321 amino acid (SEQ ID No: 1) sequence given in the specification, and the variable region of each of the heavy chains is encoded by a sequence of nucleic acids of which at least 70 % is identical to the murine sequence of nucleic acids having a fully defined 366 amino acid (SEQ ID No: 2) sequence given in the specification, the constant regions of the light and heavy chains are constant regions of a murine species. Independent claims are included for: (1) a stable cellular line expressing (I); (2) a R565 clone registered under the registration number 1-3510 in the National Collection of Cultures and of Micro-organisms; (3) a DNA fragment of a sequence having a fully defined 1356 amino acid (SEQ ID No: 6) sequence for the heavy chain; and (4) a DNA fragment of sequence having a fully defined 642 amino acid (SEQ ID No: 5) sequence for the light chain. ACTIVITY : Antianemic. MECHANISM OF ACTION : Human anti-factor-VIII inhibitor; B-cell antigen receptor binder.
机译:用于靶向抑制人因子VIII的抗体的单克隆抗独特型抗体(I)是新的,其中(I)靶向人因子VIII的C2区,其中每个轻链的可变区由与鼠科动物核酸序列(SEQ ID No:1)相同的核酸序列,每个重链的可变区由与鼠科动物核酸序列(SEQ ID No.1)相同的核酸序列编码:2),轻链和重链的恒定区是鼠类的恒定​​区。靶向抑制人因子VIII的抗体的单克隆抗独特型抗体是新的,其中(I)靶向人因子VIII的C2区,其中每个轻链的可变区由一个序列编码至少70%的核酸与说明书中具有完全定义的321个氨基酸(SEQ ID No:1)序列的核酸的鼠科序列相同的核酸,并且每个重链的可变区均被编码通过至少具有与说明书中给出的具有完整定义的366个氨基酸(SEQ ID No:2)序列的核酸的鼠科动物序列至少70%相同的核酸序列,轻链和重链的恒定区是鼠类的恒定​​区。包括以下独立权利要求:(1)表达(I)的稳定细胞系; (2)在国家文化和微生物收藏中以注册号1-3510注册的R565克隆; (3)具有对重链具有完全定义的1356个氨基酸(SEQ ID No:6)序列的序列的DNA片段; (4)具有轻链完全定义的642个氨基酸(SEQ ID No:5)序列的序列的DNA片段。活动:抗贫血。作用机理:人类抗VIII因子抑制剂; B细胞抗原受体结合剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号